Vaccines, Pneumococcal Clinical Trial
Official title:
A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of Three Lots of 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United States
The purpose of this study will be to evaluate safety, tolerability and immunogenicity of three lots of 13-valent pneumococcal vaccine given to healthy infants. Lots will be studied for consistency of the immune response, as well as for non-inferiority and safety as compared to 7-valent Pneumococcal Conjugate Vaccine.
Status | Completed |
Enrollment | 1712 |
Est. completion date | June 2009 |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 42 Days to 98 Days |
Eligibility |
Inclusion criteria: - Healthy 2 month old infants - Available for the duration of the study and reachable by telephone - Able to complete two blood drawing procedures during the study Exclusion criteria: - Previous vaccination, contraindication or history of allergic reaction to vaccines or vaccine components - Bleeding disorder, immune deficiency or significant chronic or congenital disease - Previous receipt of blood products or immune globulin |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Wyeth is now a wholly owned subsidiary of Pfizer |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age) | Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Participants may be represented in more than 1 category. | Within 7 days after dose (2 months of age) | Yes |
Other | Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age) | Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Participants may be represented in more than 1 category. | Within 7 days after dose (4 months of age) | Yes |
Other | Percentage of Participants Reporting Local Reactions in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age) | Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Participants may be represented in more than 1 category. | Within 7 days after dose (6 months of age) | Yes |
Other | Percentage of Participants Reporting Local Reactions in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age) | Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Induration and erythema were scaled as Any (induration or erythema present); Mild (0.5 cm to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (> 7.0 cm). Participants may be represented in more than 1 category. | Within 7 days after dose (12 months of age) | Yes |
Other | Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 1 (2 Months of Age) | Systemic events (any fever = 38 degrees Celsius [C], decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category. | Within 7 days after dose (2 months of age) | Yes |
Other | Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 2 (4 Months of Age) | Systemic events (any fever = 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category. | Within 7 days after dose (4 months of age) | Yes |
Other | Percentage of Participants Reporting Systemic Events in the Three 13vPnC Groups and 7vPnC Group: Infant Series Dose 3 (6 Months of Age) | Systemic events (any fever = 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category. | Within 7 days after dose (6 months of age) | Yes |
Other | Percentage of Participants Reporting Systemic Events in the Combined 13vPnC Group and 7vPnC Group: Toddler Dose (12 Months of Age) | Systemic events (any fever = 38 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives [urticaria]) were reported using an electronic diary. Participants may be represented in more than 1 category. | Within 7 days after dose (12 months of age) | Yes |
Primary | Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Infant Series | Antibody geometric mean concentration (GMC) as measured by micrograms per milliliter (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. | 1 Month after the infant series (7 Months of age) | No |
Primary | Percentage of Participants Achieving Predefined Antibody Level =0.1 International Units Per Milliliter (IU/mL) for Tetanus Toxoid in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series | Percentage of participants achieving predefined antibody threshold =0.1 IU/ mL along with the corresponding 95% CI for concomitant antigen tetanus toxoid are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot. | 1 month after the infant series (7 months of age) | No |
Primary | Percentage of Participants Achieving Predefined Antibody Level =1:8 for Poliovirus in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series | Percentage of participants achieving predefined antibody threshold =1:8 along with the corresponding 95% CI for concomitant antigen poliovirus type 1, type 2, and type 3 (Sabin strains 1, 2, 3) are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot. | 1 month after the infant series (7 months of age) | No |
Primary | Percentage of Participants Achieving Predefined Antibody Level =10.0 Milli-International Units Per Milliliter (mIU/mL) for Hepatitis B in the Combined 13vPnC Group Relative to 7vPnC Group 1 Month After the Infant Series | Percentage of participants achieving predefined antibody threshold =10.0 mIU/ mL along with the corresponding 95% CI for concomitant antigen hepatitis B are presented. Exact 2-sided CI was based on the observed proportion of participants. Combined 13vPnC group includes participants randomized to pilot lot 1, pilot lot 2, or the manufacturing lot. | 1 month after the infant series (7 months of age) | No |
Secondary | Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level =0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Infant Series | Percentage of participants achieving predefined antibody threshold =0.35mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. | 1 month after the infant series (7 months of age) | No |
Secondary | Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level =0.35 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose | Percentage of participants achieving predefined antibody threshold =0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. | 1 month after the toddler dose (13 months of age) | No |
Secondary | Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level =1.00 Mcg/mL in the Combined 13vPnC Group 1 Month After the Infant Series | Percentage of participants achieving predefined antibody threshold =1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. | 1 month after the infant series (7 months of age) | No |
Secondary | Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level =1.00 Mcg/mL in the Three 13vPnC Groups 1 Month After the Toddler Dose | Percentage of participants achieving predefined antibody threshold =1.00 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. | 1 month after the toddler dose (13 months of age) | No |
Secondary | Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody in the Three 13vPnC Groups 1 Month After the Toddler Dose | Antibody geometric mean concentration (GMC) as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. | 1 month after the toddler dose (13 months of age) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00373958 -
Study Comparing 13-valent Pneumococcal Conjugate Vaccine With 7-valent Pneumococcal Conjugate Vaccine
|
Phase 3 | |
Completed |
NCT00580684 -
Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children
|
Phase 4 | |
Completed |
NCT00366899 -
Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants
|
Phase 3 | |
Completed |
NCT00366340 -
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
|
Phase 3 | |
Completed |
NCT00384059 -
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
|
Phase 3 | |
Completed |
NCT00368966 -
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.
|
Phase 3 | |
Completed |
NCT00366678 -
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
|
Phase 3 | |
Completed |
NCT00366548 -
Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants
|
Phase 3 | |
Completed |
NCT00294294 -
Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa
|
Phase 4 | |
Completed |
NCT00708682 -
Study Evaluating 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants in Mexico
|
Phase 3 | |
Completed |
NCT00474539 -
Study Evaluating a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
|
Phase 3 | |
Completed |
NCT01086397 -
Epidemiologic Study Of The Distribution Of Vaccine-Type Streptococcus Pneumoniae Serotypes In Adults In The US With Community-Acquired Pneumonia
|
N/A |